Drug Profile


Alternative Names: MIM-D3

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Mimetogen Pharmaceuticals
  • Class Amides; Aza compounds; Cyclic ethers; Eye disorder therapies; Neuroprotectants; Nitrobenzoates; Small molecules
  • Mechanism of Action TrkA receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Dry eyes
  • No development reported Glaucoma

Most Recent Events

  • 01 Mar 2017 Mimetogen Pharmaceuticals completes two phase III clinical trials in Dry eyes in USA (NCT02665234; NCT02634853)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Glaucoma in Canada (Ophthalmic, Liquid)
  • 04 Nov 2015 Allergan and Mimetogen Pharmaceuticals enter into an exclusive licensing agreement for development and commercialisation of tavilermide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top